




Codes ATC: J01GB06

Indication	Inflammatory and other diseases of prostate <span>Code ICD11: GA91.Z</span>
INN	Amikacin
Type de médicament	Chemical agent
Groupes d'antibiotiques	<span>A ACCESS</span>
Type de liste	Liste de base
Formulations	Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
Historique des statuts LME	Ajouté pour la première fois en 2017 (TRS 1006) Modifié en 2023 (TRS 1049)
Sexe	Mâle
Âge	Adolescents et adultes
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite <a href="#">sur les brevets.</a> 
Wikipédia	<a href="#">Amikacin</a> 
DrugBank	<a href="#">Amikacin</a> 

### Recommandation du comité d'experts

In consideration of the review of the age appropriateness of formulations of medicines on the EMLc, and the comparison report of the EML versus EMLc, the Expert Committee recommended changes to the EMLc for addition of new, age-appropriate formulations and strengths of existing essential medicines, deletion of unavailable or age-inappropriate formulations and strengths, and other listing modifications as proposed in the application. The Committee also endorsed the proposals for further review of the public health relevance and evidence for specific medicines for use in children for potential future consideration for inclusion on the EMLc. The Committee noted and welcomed the ongoing review being coordinated by the Secretariat for the remaining sections of the EMLc for consideration by the 2025 Expert Committee. As a result of the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of a new strength formulation of amikacin (injection 50 mg/mL (as sulfate) in 2 mL vial) to the EMLc. - the addition of new strength formulations of cefotaxime (powder for injection: 500 mg; 1 g; 2 g (as sodium) in vial) to the EML and EMLc. - the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc. - the addition of a new strength formulation of ciprofloxacin (solid oral dosage form 100 mg (as hydrochloride)) to the EMLc.

### Recommandations de la LME : Inflammatory and other diseases of prostate

**Premier choix**

**Second choix**

**MILD TO MODERATE**

ciprofloxacin

cefotaxime

ceftriaxone

## SEVERE

cefotaxime

co-prescrire avec [amikacin](#)

ceftriaxone

co-prescrire avec [amikacin](#)

